OakChart

Cg Oncology Inc

CGONHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

72.61-0.03 (-0.04%)
2026-11-12 03:04 CET
Market cap
6,485.45 USD m
Revenue, TTM
6.17 USD m
Net income, TTM
-237.46 USD m
Free cash flow, TTM
-189.17 USD m
EPS diluted, TTM
-2.76
P/E
-
Compare

Price

CGON against its 20, 50 and 200-day averages
2050200beatmiss
50.0060.0070.0080.002.4M4.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CGONclose 72.6120-day 65.0650-day 68.13200-day 66.4972.6152w high

10.3% under the 52-week high of 80.97 on 19 Aug 2026. 52-week low 35.80 on 11 Nov 2025. Last 15 sessions, 33.7% high to low

Volume 0.94× normal · the line is the 50-bar volume average

Profile

CGON
52-week range, 81% of the way up
35.8080.97

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Dallas, TX.

IndexRUT
Employees142
IPOJan 25, 2024
Beta0.29
ATR, 14d3.99
Rel volume0.94
Short float15.48%
Insider own33.33%
Inst own89.11%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap6.49B
Enterprise Value5.51B
Income-237.46M
Sales6.17M
Book/sh11.10
Cash/sh11.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees142
IPOJan 25, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S1051.13
P/B6.54
P/C6.59
P/FCF-
EV/EBITDA-
EV/Sales893.07
Quick Ratio21.68
Current Ratio21.70
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.76
EPS next Y-3.08
EPS next Q-0.74
EPS this Y-45.83%
EPS next Y-1.45%
EPS next 5Y28.84%
EPS past 3/5Y-46.89% -65.75%
Sales past 3/5Y176.56% -20.97%
EPS Y/Y TTM-39.33%
Sales Y/Y TTM183.62%
EPS Q/Q-12.14%
Sales Q/Q-3.72%
EarningsNov 06 BMO
EPS/Sales Surpr.23.27% 192.86%

Ownership

Insider Own33.33%
Insider Trans1.12%
Inst Own89.11%
Inst Trans3.43%
ROA-26.73%
ROE-28.29%
ROIC-23.77%
Gross Margin-106.23%
Oper. Margin-4293.53%
Profit Margin-3851.09%
SMA2011.60%
SMA506.58%
SMA2009.21%
Trades-

Technical

Shs Outstand89.30M
Shs Float59.55M
Short Float15.48%
Short Ratio9.76
Short Interest9.22M
52W High80.97 -10.32%
52W Low35.80 102.82%
Volatility8.52% 5.56%
ATR (14)3.99
RSI (14)60.35
Beta0.29
Rel Volume0.94
Avg Volume943.94K
Volume890,202

Performance

Perf Week7.24%
Perf Month16.36%
Perf Quarter-2.81%
Perf Half Y-1.88%
Perf YTD74.88%
Perf Year86.95%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.13
Target Price91.46
Prev Close72.64
Price72.61
Change %-0.04%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
May 19, 2026InitiatedWWolfe ResearchPeer Perform
Dec 11, 2025InitiatedWWedbushOutperform$70-3.6%
Nov 24, 2025InitiatedTTruistBuy
Oct 08, 2025InitiatedGGuggenheimBuy$90+23.9%
Aug 19, 2025InitiatedPPiper SandlerOverweight$55-24.3%
Jul 10, 2025ResumedGGoldmanBuy$40-44.9%
May 02, 2025InitiatedJJP MorganOverweight$41-43.5%
Apr 16, 2025InitiatedBScotiabankSector Perform$23-68.3%
Jan 07, 2025InitiatedTTD CowenBuy
Oct 24, 2024InitiatedUUBSBuy$60-17.4%

Peers

Mkt cap
TickerCompanyMkt cap
IBRXImmunityBio Inc7.10B
URGNUroGen Pharma Ltd1.28B
ENGNenGene Therapeutics Inc120.63M
TARAProtara Therapeutics Inc161.32M
AURAAura Biosciences Inc792.01M
CADLCandel Therapeutics Inc705.50M
JNJJohnson & Johnson675.03B
REPLReplimune Group Inc2.06B
TLXTelix Pharmaceuticals Ltd ADR3.31B
IOVAIovance Biotherapeutics Inc3.74B

Insider trading

latest 14 of 60
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
POST LEONARD EDirectorOct 15 '26Option Exercise0.601,0006001,000Oct 19 04:30 PM
POST LEONARD EDirectorOct 15 '26Sale62.061,00062,0650Oct 19 04:30 PM
LEONARD POSTDirectorOct 15 '26Proposed Sale61.843,000185,520Oct 15 04:41 PM
AMBAW BELLETEOfficerSep 21 '26Proposed Sale76.0130,7872,340,024Sep 21 04:04 PM
AMBAW BELLETEOfficerSep 17 '26Proposed Sale76.506,532499,698Sep 17 04:33 PM
POST LEONARD EDirectorSep 15 '26Option Exercise0.601,0006001,000Sep 17 04:30 PM
POST LEONARD EDirectorSep 15 '26Sale72.981,00072,9800Sep 17 04:30 PM
AMBAW BELLETEOfficerSep 11 '26Proposed Sale75.0082661,950Sep 11 05:10 PM
AMBAW BELLETEOfficerSep 02 '26Proposed Sale77.6129,6302,299,448Sep 02 05:02 PM
AMBAW BELLETEOfficerAug 31 '26Proposed Sale75.5050,0003,775,250Aug 31 04:50 PM
AMBAW BELLETEOfficerAug 27 '26Proposed Sale79.395,789459,561Aug 27 05:07 PM
AMBAW BELLETEOfficerAug 25 '26Proposed Sale79.5510,551839,338Aug 25 04:38 PM
AMBAW BELLETEOfficerAug 24 '26Proposed Sale79.525,762458,185Aug 24 05:12 PM
AMBAW BELLETEOfficerAug 19 '26Proposed Sale79.54100,0007,954,105Aug 19 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200
  • CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) +17.27%
  • CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer (GlobeNewswire)
  • 3 Stocks Call Traders Are Targeting Today (Schaeffer's Research)
  • CG Oncology to Present at Upcoming Investor Conferences in September (GlobeNewswire)
  • CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology (GlobeNewswire) +6.06%
  • CG Oncology to Present at Upcoming Investor Conferences in June (GlobeNewswire)
  • SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
  • CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients (GlobeNewswire)
  • CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC (GlobeNewswire)
  • CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • CG Oncology to Present at Upcoming Investor Conferences in May (GlobeNewswire)
  • CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026 (MarketBeat)
  • H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating (Insider Monkey)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-0.640-0.834-0.6401.600.5514
2026Q22026-08-06-0.900-0.664-0.8961.160.3614
2026Q12026-05-08-0.710-0.556-0.7121.080.4514
2025Q42026-02-27-0.550-0.600-0.5162.280.4515
2025Q32025-11-14-0.570-0.559-0.5711.670.0613
2025Q22025-08-08-0.540-0.466-0.5440.000.1010
2025Q12025-05-13-0.450-0.404-0.4520.050.199
2024Q42025-03-28-0.460-0.345-0.4180.460.117
2024Q32024-11-12-0.300-0.349-0.2680.040.117
2024Q22024-08-08-0.280-0.356-0.2480.110.215
2024Q12024-05-09-0.360-0.312-0.2220.530.175
2023Q42024-02-28-0.260-0.675-0.3310.070.002
2026Q4---0.737--0.8914
2027Q1---0.781--0.527
2027Q2---0.779--9.587
2027Q3---0.801--14.127

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-1.125-1.333-1.0170.150.10
2024FY-1.410-1.274-1.1561.141.28
2025FY-2.080-2.176-2.0834.042.81
2026FY--3.033--5.50
2027FY--3.077--73.24
2028FY--0.749--390.26
2029FY-3.152--973.3
2030FY-6.722--1,565

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0612500.890.002.22
2026Q4S2026-11-0212010.520.001.20
2026Q4S2026-10-2112110.520.001.20
2026Q4S2026-10-2012120.520.001.20
2026Q4S2026-09-0912440.520.001.20
2026Q4S2026-08-1912530.550.001.27
2026Q4S2026-08-0712430.540.001.27
2026Q4S2026-08-0612420.600.001.46
2026Q4S2026-07-2812009.380.00101
2026Q4S2026-07-2612109.380.00101
2026Q4S2026-07-2212119.380.00101
2026Q4S2026-07-2112139.380.00101
2026Q4S2026-05-1413138.660.00101
2026Q4S2026-05-1313048.630.00101

Estimate history

EPS, annual-0.276-0.657-1.017-1.156-2.083-2.7645
Period20212022202320242025TTM
EPS, quarterly-0.268-0.418-0.452-0.544-0.571-0.516-0.712-0.896-0.64
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual10.3580.1910.2041.1394.046.17
Period20212022202320242025TTM
Sales, quarterly0.0430.4560.05201.6662.3221.0831.1571.604
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual66.63666.63666.63676.15580.68989.301
Period20212022202320242025MRQ
Shares, quarterly76.15576.15576.22176.23278.27780.68988.00888.30689.301
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue6.174.041.140.200.1910.36
Cost of Goods Sold Incl. D&A12.724.690.030.020.010.01
Gross Profit-6.55-0.651.110.190.1810.35
Selling, General and Administrative Excl. Other258.19190.12115.7755.6435.4222.95
Research and Development167.57116.6482.1045.7529.0318.32
Other Operating Expense0.000.000.000.000.000.00
Operating Income-264.74-190.77-114.67-55.45-35.25-12.61
Interest Expense----0.000.45
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-237.46-161.00-88.04-48.61-35.44-12.84
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-237.46-161.00-88.04-48.61-35.44-12.84
Net Income From Continuing Operations-237.46-161.00-88.04-48.61-35.44-12.84
Net Income-237.46-161.00-88.04-67.80-43.79-18.38
EPS (Recurring)-2.67-2.08-1.16-1.02-0.66-0.28
EPS (Basic, Before Extraordinaries)-2.76-2.08-1.16-1.02-0.66-0.28
EPS (Diluted)-2.76-2.08-1.16-1.02-0.66-0.28
EBITDA-261.04-189.33-114.63-55.43-35.23-12.60
Non-Operating Income (Expense)27.2829.7826.636.84-0.200.22
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense36.4526.6811.401.530.681.11
Price To Sales Ratio1,021.74794.471,917.58---
Gross Margin-106.23-16.1497.1991.6792.1599.90
Operating Margin-4,293.53-4,722.13-10,067.25-27,180.88-18,453.40-121.70
Net Margin-3,851.09-3,985.02-7,729.50-33,234.31-22,925.65-177.48
Shares Outstanding89.3080.6976.1566.6466.6466.64
Market Capitalization6,485.456,485.451,939.621,927.45--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.601.161.082.321.670.000.050.46
Cost of Goods Sold Incl. D&A2.673.923.003.121.990.160.02-
Gross Profit-1.06-2.77-1.92-0.80-0.33-0.160.03-
Selling, General and Administrative Excl. Other62.1883.6364.4747.9050.8048.5942.2338.51
Research and Development39.2254.6643.7329.9627.8831.3327.4726.80
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-63.25-86.40-66.39-48.70-51.13-48.74-42.20-38.05
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-56.89-79.06-60.20-41.31-43.81-41.43-34.45-31.80
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-56.89-79.06-60.20-41.31-43.81-41.43-34.45-31.80
Net Income From Continuing Operations-56.89-79.06-60.20-41.31-43.81-41.43-34.45-31.80
Net Income-56.89-79.06-60.20-41.31-43.81-41.43-34.45-31.80
EPS (Recurring)-0.64-0.90-0.71-0.52-0.57-0.54-0.45-0.42
EPS (Basic, Before Extraordinaries)-0.64-0.90-0.71-0.52-0.57-0.54-0.45-0.42
EPS (Diluted)-0.64-0.90-0.71-0.52-0.57-0.54-0.45-0.42
EBITDA-62.09-85.55-65.55-47.85-50.71-48.59-42.18-38.05
Non-Operating Income (Expense)6.367.346.197.397.327.327.756.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.4614.336.477.197.337.015.154.99
Price To Sales Ratio1,021.741,006.201,128.02823.191,421.653,596.912,818.481,917.58
Gross Margin-66.40-239.24-177.29-34.32-19.63-53.85-
Operating Margin-3,943.20-7,467.68-6,130.10-2,097.33-3,068.97--81,161.54-8,344.08
Net Margin-3,546.82-6,832.84-5,558.82-1,779.03-2,629.53--66,253.85-6,973.25
Shares Outstanding89.3088.3188.0180.6978.2876.2376.2276.15
Market Capitalization6,485.456,266.795,714.573,349.263,071.251,981.861,881.561,939.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments742.15742.00187.67143.4853.61
Short Term Receivables0.690.780.090.300.00
Inventories1.560.000.000.000.00
Other Current Assets15.0711.436.363.424.80
Total Current Assets759.48754.21194.12147.2158.41
Net Property, Plant & Equipment19.570.490.490.510.20
Total Investments and Advances0.000.000.000.000.00
Intangible Assets10.87----
Other Assets1.680.094.690.030.09
Total Assets791.59754.80199.30147.7558.69
Short Term Debt Incl. Current Port. of LT Debt0.920.190.579.153.02
Accounts Payable5.716.523.240.981.00
Other Current Liabilities24.2114.6610.445.291.96
Total Current Liabilities30.8421.3714.2515.435.97
Long Term Debt6.110.050.267.1412.46
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities0.31----
Other Liabilities1.740.000.000.000.00
Total Liabilities38.9921.4214.5122.5718.44
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00307.89202.8782.87
Common Equity752.60733.38-123.10-77.69-42.62
Total Shareholders Equity752.60733.38184.79125.1840.25
Accumulated Minority Interest0.000.000.000.000.00
Total Equity752.60733.38184.79125.1840.25
Total Liabilities & Stockholders Equity791.59754.80199.30147.7558.69
Book Value Per Share9.339.63-1.85-1.17-0.64
Tangible Book Value Per Share9.199.63-1.85-1.17-0.64
Full-Time Employees14211361--
Price to Book Ratio6.543.613.59--
Return on Assets-20.82-18.45-28.01-34.34-
Return on Equity-21.67-19.18-31.36-42.85-
Return on Invested Capital-21.22-12.00-26.27-26.79-24.35
Quick Ratio24.5835.3013.629.549.78
Current Ratio24.6335.3013.629.549.78

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-237.46-161.00-88.04-48.61-35.44-12.84
Depreciation3.691.450.030.020.010.01
Other Funds (Non Cash)47.6824.936.39-0.531.191.14
Funds from Operations-186.08-134.62-81.62-49.12-34.24-11.69
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.202.282.913.444.44-1.97
Cash from Operating Activities-187.28-132.35-78.71-45.68-29.80-13.65
Capital Expenditures-1.89-0.13-0.230.00-0.01-0.10
Net Assets From Acquisitions0.00-21.970.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-331.99-223.72-300.53-121.19-55.340.00
Purchase of Investments-1,203.68-1,067.86-1,045.94-517.61-55.340.00
Sale Or Maturity of Investments871.69844.14745.41396.420.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-333.89-245.82-300.76-121.19-55.35-0.10
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock504.47153.59628.64103.29119.690.24
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock504.47153.59628.64103.29119.690.24
Proceedsfrom Stock Options489.77147.13626.04101.21119.530.00
Issuance or Reduction of Debt, Net0.000.00-0.36-16.290.0015.20
Change in Long Term Debt0.000.00-0.36-16.290.0015.20
Issuance of Long Term Debt0.000.000.000.000.0015.20
Reduction of Long Term Debt0.000.00-0.36-16.290.000.00
Net Financing Active Other Cash Flow-0.200.000.000.000.000.00
Other Financing Activities Uses-0.200.000.000.000.000.00
Cash from Financing Activities504.27153.59628.2887.00119.6915.45
Net Change in Cash-16.90-224.58248.80-79.8834.541.70
Free Cash Flow-189.17-132.48-78.95-45.68-29.82-13.75
Preferred Dividends (Cash Flow)-0.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments984.461,028.281,076.24742.15680.26661.05
Short Term Receivables0.670.421.270.690.520.56
Inventories1.171.001.491.561.500.00
Other Current Assets21.4419.9523.1315.0713.5111.42
Total Current Assets1,007.731,049.651,102.14759.48695.79673.03
Net Property, Plant & Equipment21.1920.4419.5919.5719.531.22
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets10.8310.8410.8610.8714.48-
Other Assets6.924.732.681.680.110.52
Total Assets1,046.671,085.651,135.26791.59729.91701.45
Short Term Debt Incl. Current Port. of LT Debt1.130.981.070.920.910.29
Accounts Payable9.7712.738.245.719.197.12
Other Current Liabilities35.5333.5325.9124.2120.4222.97
Total Current Liabilities46.4347.2435.2230.8430.5330.38
Long Term Debt8.117.836.516.116.330.71
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.310.310.310.311.61-
Other Liabilities0.851.161.451.743.800.00
Total Liabilities55.7056.5443.4838.9942.2731.09
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity990.971,029.121,091.78752.60687.64670.36
Total Shareholders Equity990.971,029.121,091.78752.60687.64670.36
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity990.971,029.121,091.78752.60687.64670.36
Total Liabilities & Stockholders Equity1,046.671,085.651,135.26791.59729.91701.45
Book Value Per Share11.1011.6512.419.338.788.79
Tangible Book Value Per Share10.9811.5312.289.198.608.79
Full-Time Employees---142--
Price to Book Ratio6.545.737.264.734.582.81
Return on Assets-26.73-25.11-20.04-20.82-23.63-20.24
Return on Equity-28.29-26.41-20.79-21.67-24.74-20.95
Return on Invested Capital-5.69-7.62-5.48-5.44-6.31-6.17
Quick Ratio21.6822.2031.2524.5822.7422.15
Current Ratio21.7022.2231.3024.6322.7922.15

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-56.89-79.06-60.20-41.31-43.81-41.43
Depreciation1.160.850.840.850.420.16
Other Funds (Non Cash)13.8517.418.208.237.374.65
Funds from Operations-41.89-60.80-51.16-32.23-36.02-36.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.8214.38-5.78-3.98-2.878.66
Cash from Operating Activities-47.71-46.41-56.94-36.22-38.89-27.96
Capital Expenditures-1.11-0.47-0.30-0.01-0.10-0.01
Net Assets From Acquisitions0.000.000.000.00-21.970.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments47.1530.90-334.54-75.5011.112.42
Purchase of Investments-122.55-196.01-587.39-297.74-240.27-167.96
Sale Or Maturity of Investments169.69226.90252.85222.24251.38170.38
Other Uses0.000.000.000.0026.00-1.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities46.0330.43-334.85-75.5015.041.41
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock10.291.94393.1799.0754.37-0.30
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock10.291.94393.1799.0754.37-0.30
Proceedsfrom Stock Options0.00-0.14391.5098.4149.27-0.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-0.02-0.170.000.000.00
Other Financing Activities Uses-0.00-0.02-0.170.000.000.00
Cash from Financing Activities10.281.92393.0099.0754.37-0.30
Net Change in Cash8.61-14.061.21-12.6530.52-26.85
Free Cash Flow-48.82-46.88-57.25-36.22-38.99-27.97

Revenue breakdown

Commercial And Development2025: 3.23M
License And Collaboration2024: 1.14M 2025: 806.00K
United States2024: 1.14M 2025: 4.04M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.60%9.2M59.1M867.41K
2026-10-1515.02%8.9M59.1M878.10K
2026-09-3017.67%10.4M59.1M888.38K
2026-09-1519.05%11.3M59.1M937.83K
2026-08-3119.95%11.4M57.1M976.72K
2026-08-1419.19%11.2M58.6M1.03M
2026-07-3120.64%11.8M57.4M1.05M
2026-07-1521.20%12.1M57.1M1.06M
2026-06-3021.14%12.1M57.1M1.11M
2026-06-1518.38%10.6M57.5M1.10M
2026-05-2917.07%9.8M57.5M1.23M
2026-05-1514.72%9.2M62.4M1.20M
2026-04-3016.47%9.2M56.0M1.19M
2026-04-1517.02%9.5M56.0M1.26M
2026-03-3119.78%10.5M53.3M1.33M
2026-03-1319.82%10.6M53.3M1.21M
2026-02-2717.45%9.3M53.3M1.04M
2026-02-1318.66%9.5M50.9M1.06M
2026-01-3018.24%9.2M50.7M1.08M
2026-01-1518.52%9.4M50.7M993.80K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call40.0032.2036.500.004.4420.000.000.921-0.3190.017
call45.0027.3032.000.003.9880.000.000.875-0.4660.023
call50.0023.7028.0031.003.72610.000.000.839-0.5110.028
call55.0019.6024.0021.643.43511.000.000.790-0.5950.033
call60.0016.5020.5018.003.2567440.000.740-0.6330.037
call65.0013.3017.5016.003.1533,3511.000.682-0.6820.040
call70.0011.1014.5012.852.9932,5101.000.618-0.6630.043
call75.009.2012.009.803.0048,1054.000.564-0.7480.044
call80.006.0010.008.462.8873810.000.504-0.7390.045
call85.004.508.506.252.8496,6731710.448-0.7230.045
call90.003.507.005.362.80571.000.000.393-0.6920.043
call95.002.454.905.332.5611420.000.318-0.5860.040
call1001.554.902.502.78870.001.000.302-0.6230.039
call1050.452.202.302.2221036.000.186-0.3820.030
call1100.004.901.952.3931.000.000.177-0.3990.029
call1150.004.902.002.55382.000.000.169-0.4130.029
put40.000.501.901.003.4562012.00-0.084-0.3400.017
put45.001.603.201.953.51599.000.00-0.125-0.4610.023
put50.002.554.002.653.2536,0440.00-0.161-0.5060.028
put55.002.905.603.403.2101,3837.00-0.210-0.5890.033
put60.003.707.005.003.0301,23433.00-0.260-0.6260.037
put65.005.709.106.402.9733,0663.00-0.318-0.6750.040
put70.007.0010.009.402.569804601-0.382-0.6550.043
put75.009.5014.2012.502.8655630.00-0.436-0.7390.044
put80.0012.5017.2015.502.8182,0830.00-0.496-0.7310.045
put85.0015.6020.4015.302.7584.000.00-0.552-0.7140.045
put90.0019.0023.800.002.6890.000.00-0.607-0.6820.043
put95.0023.0027.900.002.7340.000.00-0.682-0.5760.040
put10027.0031.500.002.6090.000.00-0.698-0.6120.039
put10531.5036.300.002.7600.000.00-0.814-0.3710.030
put11036.0040.700.002.7760.000.00-0.823-0.3860.029
put11541.0045.400.002.8550.000.00-0.831-0.4000.029

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-193Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-31144Filing for proposed sale of securities under Rule 144.SEC
2026-08-27144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-06144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100062.07K1
2026-090072.98K1
2026-080074.54K1
2026-07001.89M2
2026-0624.81M1847.58K4
2026-050000
2026-04001.14M1
2026-0300124.71K1
2026-020000
2026-0100584.80K1
2025-120000
2025-110041.43K1

Institutional holders

Manager% owned
RTW INVESTMENTS, LP9.65%
T. Rowe Price Investment Management, Inc.7.50%
Decheng Capital LLC7.22%
BlackRock, Inc.7.09%
WELLINGTON MANAGEMENT GROUP LLP6.04%
FMR LLC5.18%
PRICE T ROWE ASSOCIATES INC /MD/4.31%
TCG Crossover Management, LLC4.16%
VANGUARD PORTFOLIO MANAGEMENT LLC3.93%
STATE STREET CORP3.90%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND3.24%
T. Rowe Price Capital Appreciation Fund2.92%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.70%
iShares Russell 2000 ETF2.15%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.06%
VANGUARD SMALL-CAP INDEX FUND1.95%
T. Rowe Price New Horizons Fund, Inc.1.26%
VANGUARD EXTENDED MARKET INDEX FUND0.98%
Fidelity Small Cap Index Fund0.91%
Fidelity Small Cap Growth Fund0.90%

OakChart. CGON. Cached 15 minutes.